Last reviewed · How we verify
ADP adoptive cell therapy
ADP adoptive cell therapy is a Adoptive Cell Therapy Biologic drug developed by USWM CT, LLC. It is currently in Phase 1 development.
Adoptive cell therapy that transfers immune cells to patients to enhance anti-tumor or anti-disease immune responses.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ADP adoptive cell therapy |
|---|---|
| Sponsor | USWM CT, LLC |
| Drug class | Adoptive Cell Therapy |
| Modality | Biologic |
| Phase | Phase 1 |
Mechanism of action
Adoptive cell therapy involves collecting, potentially modifying, and reinfusing a patient's own immune cells or donor cells to fight disease. The specific cell type, modification approach, and molecular targets for this ADP therapy have not been publicly characterized.
Approved indications
Common side effects
Key clinical trials
- Adoptive Cell Therapy Long-term Follow-up (LTFU) Study (PHASE1)
- To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma (PHASE1)
- Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADP adoptive cell therapy CI brief — competitive landscape report
- ADP adoptive cell therapy updates RSS · CI watch RSS
- USWM CT, LLC portfolio CI
Frequently asked questions about ADP adoptive cell therapy
What is ADP adoptive cell therapy?
How does ADP adoptive cell therapy work?
Who makes ADP adoptive cell therapy?
What drug class is ADP adoptive cell therapy in?
What development phase is ADP adoptive cell therapy in?
Related
- Drug class: All Adoptive Cell Therapy drugs
- Manufacturer: USWM CT, LLC — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing